van Houte Hans sold $75K of NRIX
van Houte Hans (Chief Financial Officer) sold 4,769 shares of Nurix Therapeutics, Inc. (NRIX) at an average of $15.63 ($15.38–$16.20) across 2 trades on 2026-11-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A modest CFO sell of $75K is unlikely to move the stock significantly but may attract short‑term traders looking for sell pressure.
Market read
The filing provides a new, albeit small, data point on insider activity; relevance to traders is low.
What to watch
The CFO's 10b5‑1 plan may have been pre‑scheduled, reducing the informational value of the trade.
Background
Nurix Therapeutics (NRIX) is a clinical‑stage biotech focused on targeted protein degradation. The filing is a standard Form 4 disclosure of an insider transaction.
Ticker impact
CFO van Houte Hans sold 4,769 shares for $74.6K via a 10b5‑1 plan, reducing his stake to 42,745 shares.
likely slight pressure as the market prices in the insider sell
Small‑scale CFO sale under $100K typically has limited impact but can be interpreted as a weak signal by traders.
Market effects
Minimal; the biotech sector is unlikely to be affected by a single small insider sale.
None
None
Counterpoint
The sale could be routine portfolio rebalancing and not indicative of company fundamentals.
Key entities
- CompanyNurix Therapeutics, Inc.
Biotech firm whose CFO disclosed a small share sale.
- Personvan Houte Hans
Chief Financial Officer of Nurix who executed the sale.
